These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34216176)

  • 61. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advances in liquid biopsy-based markers in NSCLC.
    Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
    Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non-small cell lung cancer patients.
    Ma Y; Wang Y; He L; Du J; Li L; Bie Z; Li Y; Xu X; Zhou W; Wu X; Yang L; Di J; Li C; Li X; Liu D; Wang Z
    Cancer Med; 2024 Sep; 13(17):e70197. PubMed ID: 39233657
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    May T; Clement MS; Halait H; Kohlmann A; Kohlmann M; Lai J; Lee N; Li-Sucholeiki X; Meldgaard P; Joshi S; Scudder S; Shrestha N; Sorensen B; Kiral M; O'Donnell P
    PLoS One; 2024; 19(4):e0295987. PubMed ID: 38593164
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer.
    Guler GD; Ning Y; Coruh C; Mognol GP; Phillips T; Nabiyouni M; Hazen K; Scott A; Volkmuth W; Levy S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
    Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients.
    Bach S; Wever BMM; van de Wiel MA; Veltman JD; Hashemi SMS; Kazemier G; Bahce I; Steenbergen RDM
    Epigenetics; 2022 Oct; 17(10):1057-1069. PubMed ID: 34605346
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.
    Mondelo-Macía P; García-González J; León-Mateos L; Anido U; Aguín S; Abdulkader I; Sánchez-Ares M; Abalo A; Rodríguez-Casanova A; Díaz-Lagares Á; Lago-Lestón RM; Muinelo-Romay L; López-López R; Díaz-Peña R
    Mol Oncol; 2021 Nov; 15(11):2923-2940. PubMed ID: 34465006
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma
    Cho YG; Park J; Han JY; Kim TY
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372399
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
    Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
    Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liquid biopsy tracking of lung tumor evolutions over time.
    Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
    Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
    [No Abstract]   [Full Text] [Related]  

  • 74. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
    Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
    Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
    Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
    Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
    Han JY; Choi JJ; Kim JY; Han YL; Lee GK
    BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
    Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
    Oxnard GR; Paweletz CP; Kuang Y; Mach SL; O'Connell A; Messineo MM; Luke JJ; Butaney M; Kirschmeier P; Jackman DM; Jänne PA
    Clin Cancer Res; 2014 Mar; 20(6):1698-1705. PubMed ID: 24429876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.